Liraglutide injection represents Meitheal’s first commercial injector pen product and its first commercial diabetes medication. In 2023, Meitheal secured an exclusive commercial license for ...

A liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is available as an injector pen and used along with diet and exercise to improve glycemic control in adults and ...